证券代码：688716 证券简称：中研股份 公告编号：2025-024 一、监事会会议召开情况 吉林省中研高分子材料股份有限公司（以下简称"公司"）第四届监事会 第五次会议通知于 2025 年 8 月 15 日以专人送达等方式送达全体监事，会议于 会议应出席监事 3 人，实际出席监事 3 人，本次会议的召集、召开和表决程序 符合《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和 国证券法》（以下简称"《证券法》"）《上海证券交易所科创板股票上市规 则》等相关法律、行政法规、规范性文件及《吉林省中研高分子材料股份有限 公司章程》（以下简称"《公司章程》"）《吉林省中研高分子材料股份有限 公司监事会议事规则》等有关规定。 二、监事会会议审议情况 本次会议经全体监事表决，形成决议如下： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 经审议，监事会认为：公司 2025 年半年度报告及其摘要的编制和审议程序 符合相关法律法规及《公司章程》等内部规章制度的规定，报告真实、准确、 完整地反映了公司的财务状况和经营情况，不存在虚假记载、误导性陈述或重 大遗漏。 吉林省中研高分子材料股份有限 ...

Meeting Overview - The fourth meeting of the board of directors of Jilin Zhongyan High Polymer Materials Co., Ltd. was held on August 27, 2025, with all 9 directors present [1] - The meeting complied with relevant laws and regulations, including the Company Law and Securities Law [1] Financial Report Approval - The board approved the 2025 semi-annual report, confirming it accurately reflects the company's financial status and operations [2] - The voting results were unanimous, with 9 votes in favor and no opposition or abstentions [2] Fund Management Report - The board approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with regulations [2] - The report indicated no misuse of funds or changes in their intended purpose [2] Quality Improvement Action Plan - The board approved the semi-annual evaluation report of the "Quality Improvement and Efficiency Recovery Action Plan" for 2025, aimed at enhancing core competitiveness [3] - The plan is designed to promote high-quality development and fulfill the responsibilities of a listed company [3] Governance Changes - The board proposed to abolish the supervisory board and amend the company’s articles of association, pending shareholder approval [4] - The decision aligns with legal requirements and the company's actual situation [4] Governance System Revisions - The board approved revisions to several governance systems to enhance compliance and operational efficiency [4][6] - The revisions include updates to the management of shareholder meetings, board meetings, and various operational protocols [6] Fund Investment Project Adjustments - The board approved the postponement of certain fundraising investment projects and changes in implementation methods, aimed at improving project quality [7] - The adjustments were made based on practical project conditions and followed necessary review procedures [7] Capital Increase for Subsidiaries - The board approved capital increases for several wholly-owned subsidiaries, including an increase of 45 million yuan for Jilin Dingyan Chemical Co., Ltd. and 70 million yuan for Zhongyan Composite (Shanghai) Technology Development Co., Ltd. [8] - The decision reflects the business development needs of the subsidiaries [8] Upcoming Shareholder Meeting - The board decided to hold the first temporary shareholder meeting of 2025 on September 12, 2025, to discuss pending matters [9] - The meeting will address various proposals requiring shareholder approval [9]

Core Viewpoint - The company, Jilin Zhongyan High Polymer Materials Co., Ltd., is adjusting the internal investment structure of certain fundraising projects and using its own funds to pay for R&D personnel costs, which will later be replaced with equivalent amounts from the raised funds [1][10]. Fundraising Overview - The company has raised a total of RMB 902.26 million through the issuance of 30,420,000 shares at a price of RMB 29.66 per share, with a net amount of RMB 799.71 million after deducting issuance costs [1][2]. - All raised funds are managed in a dedicated account, with agreements in place between the company, its subsidiaries, and the commercial banks [2]. Project Adjustment Details - The project "Shanghai Carbon Fiber PEEK Composite Material R&D Center" has undergone changes in its implementation subject, location, and total investment amount, which has increased to RMB 110.20 million [3][5]. - The internal investment structure has been adjusted, with construction investment increasing and R&D personnel costs being reduced [5][6]. Reasons for Adjustment - The adjustments are made to enhance R&D capabilities and improve resource allocation without affecting the project's implementation or the interests of shareholders [6][8]. - The company aims to prioritize laboratory construction and equipment procurement due to the urgency of the project [5][6]. Use of Own Funds - The company plans to use its own funds to pay for R&D personnel costs during the project implementation and will replace these amounts with raised funds later [7][8]. - This approach is intended to improve operational efficiency and reduce financial costs while ensuring compliance with relevant regulations [8][9]. Approval Process - The adjustments were approved by the company's board of directors and supervisory board, confirming that the changes do not adversely affect the company's operations or shareholder interests [9][10]. - The company has established operational procedures to ensure the proper management of funds and compliance with regulations [10].